1. Home
  2. CREG vs CVKD Comparison

CREG vs CVKD Comparison

Compare CREG & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CREG

Smart Powerr Corp.

HOLD

Current Price

$2.66

Market Cap

10.9M

Sector

Utilities

ML Signal

HOLD

Logo Cadrenal Therapeutics Inc.

CVKD

Cadrenal Therapeutics Inc.

HOLD

Current Price

$3.43

Market Cap

10.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CREG
CVKD
Founded
N/A
2022
Country
China
United States
Employees
N/A
5
Industry
Power Generation
Medicinal Chemicals and Botanical Products
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.9M
10.3M
IPO Year
2019
2022

Fundamental Metrics

Financial Performance
Metric
CREG
CVKD
Price
$2.66
$3.43
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$13.00
AVG Volume (30 Days)
4.8M
66.7K
Earning Date
05-14-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
23.94
EPS
N/A
N/A
Revenue
$262,509.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.16
$3.02
52 Week High
$2.66
$14.64

Technical Indicators

Market Signals
Indicator
CREG
CVKD
Relative Strength Index (RSI) 86.32 29.69
Support Level $1.08 N/A
Resistance Level $2.66 $5.99
Average True Range (ATR) 0.14 0.43
MACD 0.22 -0.11
Stochastic Oscillator 82.63 11.08

Price Performance

Historical Comparison
CREG
CVKD

About CREG Smart Powerr Corp.

Smart Powerr Corp is engaged in waste energy recycling and is a developer of energy efficiency solutions for various energy intensive industries in China. It uses Build-Operate-Transfer (BOT) model to provide energy saving and recovery facilities for multiple energy intensive industries in China. Its waste energy recycling projects allow customers which use substantial amounts of electricity to recapture previously wasted pressure, heat, and gas from their manufacturing processes to generate electricity. It provides a clean-technology and energy-efficient solution aimed at reducing the air pollution and energy shortage problems in China. The company's operations are conducted in one industry segment. All of its assets are located in the PRC.

About CVKD Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.

Share on Social Networks: